A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian
Public ClinicalTrials.gov record NCT01952249. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
SIERRA: A Phase 1b/2 Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Study identification
- NCT ID
- NCT01952249
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Interventions
- Demcizumab Drug
- Taxol Drug
Drug
Eligibility (public fields only)
- Age range
- 21 Years to 90 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 4, 2013
- Primary completion
- May 9, 2016
- Completion
- Jul 11, 2016
- Last update posted
- Sep 8, 2020
2013 – 2016
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Oklahoma Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| The University of Texas MD Anderson Cancer Center Department of Gynecologic Oncology | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01952249, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 8, 2020 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01952249 live on ClinicalTrials.gov.